Results 161 to 170 of about 70,211 (203)

Tamoxifen Therapy in Steroid-Resistant Riedels Disease

Scottish Medical Journal, 2002
Riedel s thyroiditis is a rare chronic inflammatory disorder characterised by extensive fibrosis of the thyroid gland and sometimes the surrounding tissues. We report a case of Riedel s Thyroiditis in a middle aged female presenting with goitre, stridor and dyspnoea.
M, De, A, Jaap, J, Dempster
openaire   +2 more sources

Tamoxifen induces resistance to activated protein C

Thrombosis Research, 2014
The estrogen antagonist tamoxifen (TAM) increases the thrombotic risk similar to estrogen containing oral contraceptives (OC). In OC users this risk is attributed to alterations of hemostasis resulting in acquired resistance to activated protein C (APC).
Heiko, Rühl, Lars, Schröder, Jens, Müller, Rolf, Fimmers, Shorena, Sukhitashvili, Julia, Welz, Walther C, Kuhn, Johannes, Oldenburg, Christian, Rudlowski, Bernd, Pötzsch   +9 more
openaire   +2 more sources

Tamoxifen Therapy in Steroid Resistant Reidel's Thyroiditis

Scottish Medical Journal, 2001
Riedel's thyroiditis is a rare chronic inflammatory disorder characterised by extensive fibrosis of the thyroid gland and sometimes the surrounding tissues. We report a case of Riedel's Thyroiditis in a middle aged female presenting with goitre, stridor and dyspnoea.
M, De, A, Jaap, J, Dempster
openaire   +2 more sources

Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance

Cancer Chemotherapy and Pharmacology, 1994
To study tamoxifen resistance-stimulated growth, 30 female ovariectomized nude mice were implanted with tamoxifen-resistant tumors and treated with 10-1000 micrograms/day of tamoxifen citrate subcutaneously. Tamoxifen stimulated MCF-7 tumor growth in a dose-dependent manner, with tumoral tamoxifen concentrations increasing proportionally to the dose (1-
J, Maenpaa, V, Wiebe, G, Wurz, S, Koester, V, Emshoff, R, Seymour, M, DeGregorio   +6 more
openaire   +2 more sources

Metabolic reprograming confers tamoxifen resistance in breast cancer

Chemico-Biological Interactions, 2021
Breast cancer is the most common cancer among females and the leading cause of cancer-related deaths. Approximately 70 % of breast cancers are estrogen receptor (ER) positive. An ER antagonist such as tamoxifen is used as adjuvant therapy in ER-positive patients.
Alok, Mishra, Anshuman, Srivastava, Ankit, Pateriya, Manendra Singh, Tomar, Anand Kumar, Mishra, Ashutosh, Shrivastava   +5 more
openaire   +2 more sources

Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism

The Journal of Steroid Biochemistry and Molecular Biology, 1993
Potential mechanisms for tamoxifen resistance include loss or alteration in estrogen receptor or other transcription factors and altered tamoxifen pharmacology. Using an experimental model, we have previously demonstrated that one form of tamoxifen resistance is related to the acquired ability of tamoxifen to stimulate tumor growth.
openaire   +2 more sources

NEMP1 Promotes Tamoxifen Resistance in Breast Cancer Cells

Biochemical Genetics, 2019
Breast cancer (BC) is a worldwide malignant and a leading death cancer in women. Studies have shown that adjuvant tamoxifen reduces the recurrence rate and metastasis in BC. Even though tamoxifen has been used for the therapy of BC for decades, the resistance of it on BC cells could not be ignored.
Yanyan, Liu, Chuang, Tong, Jun, Cao, Maoming, Xiong   +3 more
openaire   +2 more sources

Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.

Journal of Clinical Oncology, 1992
PURPOSE We have shown previously that acquired tamoxifen resistance in an in vivo experimental model is associated with reduced tamoxifen accumulation, isomerization of trans-4-hydroxytamoxifen, and tamoxifen-stimulated tumor growth. The purpose of this study is to isolate and verify the presence of estrogenic tamoxifen metabolites in human breast ...
V J, Wiebe, C K, Osborne, W L, McGuire, M W, DeGregorio   +3 more
openaire   +2 more sources

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

Anti-Cancer Drugs, 2004
We investigated whether it is possible to reduce anti-estrogen resistance using liposomally encapsulated tamoxifen in vivo. Small liposomal vesicles containing up to 5.1 mg tamoxifen/ml liposomal suspension, together with an alkylphospholipid to enhance the cellular uptake, were prepared and characterized.
Zeisig, Reiner, Rückerl, Dominik, Fichtner, Iduna   +2 more
openaire   +3 more sources

Tamoxifen and Multidrug Resistance in Cancer

1996
So much has been said and written about the importance of multidrug resistance in cancer that it is hard to come up with an original introduction. Suffice to say that innate or acquired resistance to radiation and chemotherapy have become the major obstacle to successful cancer treatment.
openaire   +1 more source